Prostate Specific Antigen: A Prognostic Marker of Survival in Good Prognosis Metastatic Prostate Cancer? (EORTC 30892)

This publication has 16 references indexed in Scilit:

• Prostate cancer treated by anti-androgens: is sexual function preserved?
  British Journal of Cancer, 2000
• Natural History of Progression After PSA Elevation Following Radical Prostatectomy
  JAMA, 1999
• What’s hot in the prostate?
  Prostate Cancer and Prostatic Diseases, 1999
• Follow-up in prostate cancer patients: which parameters are necessary?
  European Urology, 1999
• Endocrine treatment of prostate cancer — recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side‐effects
  BJU International, 1999
• Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
  New England Journal of Medicine, 1998
• Long-Term Efficacy and Safety of Nilutamide Plus Castration in Advanced Prostate Cancer, and the Significance of Early Prostate Specific Antigen Normalization
  Journal of Urology, 1997
• Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate Cancer
  JNCI Journal of the National Cancer Institute, 1996
• Prostate‐specific antigen and prognosis in patients with metastatic prostate cancer — a multivariable analysis of prostate cancer mortality
  British Journal of Urology, 1995
• Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic Cancer
  Cancer, 1990